CD40 and myeloid sarcoma: The most pronounced differences were observed in CD20-CD27+ B cells, where BTLA and CD40 expression were higher in MS patients, while PD-L1, CTLA-4, and CD70 were significantly reduced compared to HCs (Figure 2B).